Skip to main content
Premium Trial:

Request an Annual Quote

Novigenix Acquires Colox Colorectal Cancer Test from Diagnoplex

NEW YORK (GenomeWeb) – Novigenix today announced it has acquired Colox, a blood-based molecular diagnostic test to detect colorectal cancer and pre-cancerous polyps.

Originally developed by Diagnoplex, the Colox test can detect colorectal cancer from a whole blood sample, looking at the gene expression signature of 29 genes in peripheral blood mononuclear cells. Novigenix plans to use a proprietary algorithm to interpret gene expression data and generate the Colox test report.

Colox has been approved for sale in Europe, and has been launched commercially in Switzerland as a service provided by Unilabs' network of clinical diagnostic laboratories.

"We are committed to making Colox available to physicians and patients across Switzerland, followed by expansion in other European countries," Novigenix Executive Chairman Brian Hashemi said in a statement. The firm said it would seek partnerships to make Colox available throughout Europe.

Financial terms of the deal were not disclosed. 

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.